Water-Soluble Temozolomide Derivatives and Polymer-Temozolomide Conjugates for Enhanced Glioblastoma Treatment

LEAD INVENTOR:

Todd S. Emrick, Ph.D.

 

PRODUCT OPPORTUNITIES

• Injectable formulations of small-molecule temozolomide derivatives for treating Glioblastoma Multiforme
• Injectable formulations of temozolomide-polymer conjugates for treating Glioblastoma Multiforme

ADVANTAGES

• The new small-molecule temozolomide derivatives and polymer-temozolomide conjugates have significantly enhanced aqueous solubility.
• The conjugates provide opportunities for improving temozolomide pharmacokinetics, extending drug lifetime in circulation, reducing off-target toxicity, and enhancing targeting to glioblastoma tumor tissue.

 

TECHNOLOGY DESCRIPTION

This invention provides novel compositions of water-soluble small molecule temozolomide derivatives and water-soluble polymer-temozolomide conjugates for enhanced treatment of glioblastoma multiforme.

ABOUT THE LEAD INVENTOR

Dr. Todd Emrick is a Professor in the Department of Polymer Science and Engineering. He is a prolific inventor and a Fellow of the National Academy of Inventors.

AVAILABILITY:

Available for Licensing and/or Sponsored Research

DOCKET:

UMA 16-066

PATENT STATUS:

Patent Issued